Drug intelligence / Profile preview

LX15001

Development stage: Preclinical
Lead developer: Loxagen
Modality: Small Molecules

Overview

LX15001 is a preclinical-stage, second-generation small molecule inhibitor of arachidonate 15-lipoxygenase (ALOX15) being developed by Loxagen. It is designed to address early brain injury (EBI) following aneurysmal subarachnoid hemorrhage (SAH). By inhibiting ALOX15, LX15001 aims to mitigate secondary brain damage, including oxidative stress, mitochondrial dysfunction, blood-brain barrier disruption, and neuroinflammation, thereby improving neurological outcomes and reducing brain injury.

Targets

ALOX12 (Arachidonate 12-lipoxygenase, 12S type)15-LOX (Lysyl Oxidase)ALOX15B (Arachidonate 15-lipoxygenase B)ALOX5 (Arachidonate 5-lipoxygenase)

Beyond the preview

Go deeper on LX15001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LX15001.